Collect Product
Product Details
Synonyms
ACE-2, ACEH, ACE2
Source
Biotinylated Human ACE2, His,Avitag (AC2-H82E7) is expressed from human 293 cells (HEK293).
Predicted N-terminus: Gln 18
Request for sequenceMolecular Characterization
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 87.2 kDa. The protein migrates as 95-125 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Labeling
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
Protein Ratio
Passed as determined by the HABA assay / binding ELISA.
Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Formulation
Supplied as 0.2 μm filtered solution in PBS, pH7.4.
Contact us for customized product form or formulation.
Shipping and Storage
This product is supplied and shipped on dry ice.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 3 months under sterile conditions.
ACRO Quality Management System
Kunden haben auch angesehen
Data Display
SDS-PAGE
Biotinylated Human ACE2, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
SEC-MALS
The purity of Biotinylated Human ACE2, His,Avitag (Cat. No. AC2-H82E7) is more than 90% and the molecular weight of this protein is around 200-215 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized SARS-CoV-2 S1 protein, His Tag (Cat. No. S1N-C52H3) at 2 μg/mL (100 μL/well) can bind Biotinylated Human ACE2, His,Avitag (Cat. No. AC2-H82E7) with a linear range of 2-40 ng/mL (QC tested).
Protocol
User Reviews Publish Comment
Background Introduction
Frontier Progress
Drug Development Progress- English Name：
Angiotensin-converting enzyme 2
- Category：
- Listed Drugs Count：
0 Details
- Clinical Drugs Count：
7 Details
- Highest R&D Stage：
Phase 2 Clinical
Contact Us
Drug Candidate Licensing
